JBIO
What one share of Jade Biosciences holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our goal is to improve meaningfully upon the existing treatment paradigm through the delivery of improved dosing and convenience, a comparable safety profile, and potentially increased clinical activity.
Jade Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.89 |
|---|---|
| Cash and investments | $1.69 |
| Debt | $0.00 |
| Book value | $6.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$40.31 | — | −$32.44 | — | −$54.90 |
| 2021 | — | −$1.87 | $0.01 | −$2.24 | — | $7.06 |
| 2022 | — | −$2.10 | $0.01 | −$1.61 | — | $5.13 |
| 2023 | — | −$2.87 | $0.01 | −$2.16 | — | $3.94 |
| 2024 | — | −$2.44 | — | −$2.49 | — | — |
| 2025 | — | −$3.19 | $0.01 | −$3.03 | — | $6.74 |